TransMedics Receives FDA IDE Approval to Initiate Next-Generation OCS Heart Trial
August 4, 2025
TransMedics Group, Inc., a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced that the